Special Issue: Nanobody

Chames, Patrick; Rothbauer, Ulrich

doi:10.3390/antib9010006

Cited by 9 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 d, f), which can be selected from synthetic, naive, or immunized cDNA libraries using phage, bacterial, yeast, or ribosomal display technologies [ 233 – 235 ]. Nbs have the smallest structures (~ 13 kDa) compared with other Abs, present with antigenic recognition, can act in a monomeric form or fusion protein, and show high specificity, stability, and solubility [ 236 ]. Therefore, Nbs are valuable in biomedical research.…”

Section: Insights From Ab Therapeutic Strategies Against Sars-cov-2 Infectionmentioning

confidence: 99%

Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 is a novel β-coronavirus that caused the COVID-19 pandemic disease, which spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far. Based on the urgent need for therapeutic and prophylactic strategies, the identification and characterization of antibodies has been accelerated, since they have been fundamental in treating other viral diseases. Here, we summarized in an integrative manner the present understanding of the immune response and physiopathology caused by SARS-CoV-2, including the activation of the humoral immune response in SARS-CoV-2 infection and therefore, the synthesis of antibodies. Furthermore, we also discussed about the antibodies that can be generated in COVID-19 convalescent sera and their associated clinical studies, including a detailed characterization of a variety of human antibodies and identification of antibodies from other sources, which have powerful neutralizing capacities. Accordingly, the development of effective treatments to mitigate COVID-19 is expected. Finally, we reviewed the challenges faced in producing potential therapeutic antibodies and nanobodies by cell factories at an industrial level while ensuring their quality, efficacy, and safety.

show abstract

Section: Insights From Ab Therapeutic Strategies Against Sars-cov-2 Infectionmentioning

confidence: 99%

Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Permeabilization can be increased through a combination of detergents, collagenases, acids, denaturants, temperature changes and long, up to weeks, antibody incubation times (Hahn et al, 2021;Hong et al, 2019;Molbay et al, 2021;Noë et al, 2018). As the size of antibodies determines their ability to penetrate tissues, nanobodies, which are small (~15kDa versus monoclonal antibodies which are ~150kDa) single domain antibodies found in Camelidae (Alpaca, Llama), are emerging as a versatile option (Chames and Rothbauer, 2020;Jailkhani et al, 2019;Ramos-Gomes et al, 2018;Rousserie et al, 2015). The next step is to overcome the opaqueness of tissues.…”

Section: Tissue Clearingmentioning

confidence: 99%

Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer

Kiemen¹,

Damanakis²,

Braxton³

et al. 2023

Med

Self Cite

View full text Add to dashboard Cite

“…In addition, nanobodies can tolerate more challenging conditions, such as higher temperatures. Merging the advantages of small molecules and antibodies, nanobodies have become an emerging scaffold for PET tracers after its main patent expired in the late 2010s [ 88 ]. Other potential vectors include affibodies, DARPins, and affimers [ 89 , 90 , 91 ].…”

Section: Immuno-oncologymentioning

confidence: 99%

Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells

Amgheib

Aboagye

2022

Pharmaceutics

View full text Add to dashboard Cite

Non-invasive positron emission tomography (PET) imaging of immune cells is a powerful approach for monitoring the dynamics of immune cells in response to immunotherapy. Despite the clinical success of many immunotherapeutic agents, their clinical efficacy is limited to a subgroup of patients. Conventional imaging, as well as analysis of tissue biopsies and blood samples do not reflect the complex interaction between tumour and immune cells. Consequently, PET probes are being developed to capture the dynamics of such interactions, which may improve patient stratification and treatment evaluation. The clinical efficacy of cancer immunotherapy relies on both the infiltration and function of cytotoxic immune cells at the tumour site. Thus, various immune biomarkers have been investigated as potential targets for PET imaging of immune response. Herein, we provide an overview of the most recent developments in PET imaging of immune response, including the radiosynthesis approaches employed in their development.

show abstract

Special Issue: Nanobody

Abstract: Since their first description in 1993 [...]

Cited by 9 publications

References 22 publications

Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment

Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer

Positron Emission Tomography Probes for Imaging Cytotoxic Immune Cells

Contact Info

Product

Resources

About